Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

被引：0
|
作者：
Offidani, Massimo
Corvatta, Laura
Maracci, Laura
Liberati, Anna Marina
Ballanti, Stelvio
Attolico, Immacolata
Caraffa, Patrizia
Alesiani, Francesco
di Toritto, Tommaso Caravita
Gentili, Silvia
Tosi, Patrizia
Brunori, Marino
Derudas, Daniele
Ledda, Antonio
Gozzetti, Alessandro
Cellini, Claudia
Malerba, Lara
Mele, Anna
Andriani, Alessandro
Galimberti, Sara
Mondello, Patrizia
Pulini, Stefano
Coppetelli, Ugo
Fraticelli, Paolo
Olivieri, Attilio
Leoni, Pietro
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1974.1974
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1974
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Combination chemotherapy with bortezomib, bendamustine and prednisone for patients with refractory/relapsed multiple myeloma:: An unicentric retrospective trial
    Poenisch, W.
    Bourgeois, M.
    Wang, S. Y.
    Heyn, S.
    Jaekel, N.
    Braunert, L.
    Pfannes, R.
    Nehring, C.
    Nehring, C.
    Becker, C.
    Becker, C.
    Al Ali, H.
    Hensel, G.
    Niederwieser, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 432 - 432
  • [32] Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide
    Mele, Giuseppe
    Giannotta, Angela
    Pinna, Salvatore
    Loseto, Giacomo
    Coppi, Maria Rosaria
    Brocca, Claudio Maurizio
    Melpignano, Angela
    Quarta, Giovanni
    LEUKEMIA & LYMPHOMA, 2010, 51 (05) : 937 - 940
  • [33] Dexamethasone in relapsed/refractory multiple myeloma (MM).
    Smith, AG
    Crofts, S
    Ridge, M
    BLOOD, 1997, 90 (10) : 4143 - 4143
  • [34] Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
    Poenisch, Wolfram
    Bourgeois, Malvina
    Moll, Barbara
    Heyn, Simone
    Jaekel, Nadja
    Wagner, Ina
    Rohrberg, Robert
    Hurtz, Hans-Juergen
    Schmalfeld, Marion
    Assmann, Michael
    Edelmann, Thomas
    Mohren, Martin
    Hoffmann, Franz Albert
    Becker, Cornelia
    Schwarzer, Andreas
    Schoenfelder, Uta
    Zehrfeld, Thomas
    Hensel, Gerald
    Loeschcke, Kerstin
    Krahl, Rainer
    Al Ali, Haifa
    Niederwieser, Dietger
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (03) : 499 - 508
  • [35] Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
    Wolfram Pönisch
    Malvina Bourgeois
    Barbara Moll
    Simone Heyn
    Nadja Jäkel
    Ina Wagner
    Robert Rohrberg
    Hans-Jürgen Hurtz
    Marion Schmalfeld
    Michael Aßmann
    Thomas Edelmann
    Martin Mohren
    Franz Albert Hoffmann
    Cornelia Becker
    Andreas Schwarzer
    Uta Schönfelder
    Thomas Zehrfeld
    Gerald Hensel
    Kerstin Löschcke
    Rainer Krahl
    Haifa Al Ali
    Dietger Niederwieser
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 499 - 508
  • [36] Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma
    Schmielau, J
    Teschendorf, C
    König, M
    Schmiegel, W
    Graeven, U
    LEUKEMIA & LYMPHOMA, 2005, 46 (04) : 567 - 569
  • [37] Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
    Cerchione, Claudio
    Catalano, Lucio
    Peluso, Ilaria
    Nappi, Davide
    Di Perna, Maria
    Salvatore, Dalila
    Migliaccio, Ilaria
    Picardi, Marco
    Pane, Fabrizio
    SUPPORTIVE CARE IN CANCER, 2016, 24 (12) : 4835 - 4837
  • [38] MANAGING NEUTROPENIA BY PEGFILGRASTIM IN PATIENTS AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE
    Cerchione, C.
    Catalano, L.
    Peluso, I.
    Nappi, D.
    Di Perna, M.
    Picardi, M.
    Pane, F.
    HAEMATOLOGICA, 2016, 101 : S118 - S118
  • [39] Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
    Ludwig, Heinz
    Kasparu, Hedwig
    Leitgeb, Clemens
    Rauch, Elisabeth
    Linkesch, Werner
    Zojer, Niklas
    Greil, Richard
    Seebacher, Adelheid
    Pour, Ludek
    Weissmann, Adalbert
    Adam, Zdenek
    BLOOD, 2014, 123 (07) : 985 - 991
  • [40] Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
    Claudio Cerchione
    Lucio Catalano
    Ilaria Peluso
    Davide Nappi
    Maria Di Perna
    Dalila Salvatore
    Ilaria Migliaccio
    Marco Picardi
    Fabrizio Pane
    Supportive Care in Cancer, 2016, 24 : 4835 - 4837
12345